Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

BACKGROUND: Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell of origin, corresponding to germinal centre or activated B cell. We aimed to investigate whether adding bortezomib to standard therapy could improve ou...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Oncol
Päätekijät: Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lancet Pub. Group 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494978/
https://ncbi.nlm.nih.gov/pubmed/30948276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30935-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia